Other Invited 2019

Dr Anna Brooks

Anna Brooks

Anna Brooks holds a PhD in Immunology and is a Senior Research Fellow with the Maurice Wilkins Centre at the University of Auckland, New Zealand. In addition, she is the director of Auckland Cytometry, the flow cytometry Shared Resource Laboratory for the Faculty of Science. Anna also facilitated a collaboration with Auckland Genomics to establish a pipeline for single cell transcriptomics (scRNAseq), the first of its kind in New Zealand.

Anna is experienced in multicolour panel development, especially the characterisation of complex cellular populations in digested human tissues.  Anna’s current research interest lies in dissecting the heterogeneity of mesenchymal cells in human adipose tissue using both flow cytometric and proteogenomic techniques (CITEseq/scRNAseq). In addition, Anna is a consultant for an on-going international collaboration with the role of developing and analysing high dimensional spectral cytometry panels (26 colours) to monitor immune responses for clinical trials using the Cytek Aurora.

Anna is an active member of the international flow cytometry community, is passionate about teaching flow cytometric best practices and has presented and facilitated a number of workshops, including at the international CYTO conferences. She has also sat on a number of conference organising and national grant reviewing committees and is chairing the annual ACS meeting in 2020 in Queenstown. As well as ACS, Anna is also a member of the Australian Society for Immunology, the Australasian Society for Stem Cell Research, the International Society for Cell and Gene Therapy, the International Society for Advancement of Cytometry and the International Society for Stem Cell Research.

Dr Neil Came

Neil Came

Neil Came is a Haematopathologist, working in close collaboration with clinical and pathology colleagues to provide a high standard of care in the diagnosis and monitoring of a wide range of haematological cancers, as well as transfusion and coagulation support of all patients at Peter Mac. Neil’s research interest is disease response assessment of plasma cell myeloma. He is an active member of Australian, American and European haematology and flow cytometry societies; is currently working with ICCS and ESCCA toward an international consensus method for minimal residual disease assessment of multiple myeloma by flow cytometry; and is on the editorial board of the journal Cytometry Part B, Clinical Cytometry.

Suat Dervish

Suat Dervish

Suat Dervish is an ISAC SRL Emerging Leader. Having obtained his B.MedSci (Hons) focusing on T cell immunology from the University of Sydney and subsequently working as a Cytometry Development Specialist at the Advanced Cytometry Facility, he currently manages Westmead Cytometry driving quality data generation and technological developments to facilitate translational medical research.  He has presented workshops including “Quality Cell Sorting” at Cyto, has developed software used internationally to improve cell sorts and has developed means for >8-way simultaneous biological cell sorting. His innovative spirit has been recognised, being awarded an AMP Tomorrow Maker Grant, an Entrepreneurial Sydney University Union Kick Start Grant and with completion of the GradCert in Innovation & Enterprise. He currently teaches the Cytometry component to undergraduates as part of the AMED course at the University of Sydney and has hosted the “Build Your Own Cytometer” workshop at the Australian Cytometry Society Conferences.

Fernando Estepa

Fernando Estepa

Fernando Estepa is the Senior Scientist at the Royal College of Pathologists of Australasia Quality Assurance Programs (RCPAQAP)

He completed a Master of Applied Science (RMIT), is a NATA assessor and has assisted in both internal and external accreditation processes.

He has over 20 years experience in both Australia and the international pathology industry, working in public hospital both as a scientist and senior scientist. Fernando has worked extensively with NSW Health Pathology including the Royal Prince Alfred Hospital, Royal North Shore Hospital, and Canterbury Hospital.

He is a member of the International Society for Laboratory Haematology (ISLH) and Australian Institute of Medical Scientists (AIMS) and has been an organising committee member for quality and standardisation, ISLH, since 2018

Fernando has a strong interest in quality assurance, competency and education.

Dr Shaun Fleming

Shaun Fleming

Shaun Fleming is a clinical and laboratory haematologist at the Alfred Hospital, Northern Health and Monash Health. He has an active role in the management and research into acute leukaemias, in particular acute lymphoblastic leukaemia. He is the chief investigator on the Australasian Leukaemia & Lymphoma Group (ALLG) ALL8 study exploring the use of the novel immunotherapy blinatumomab in up-front management of adult ALL. Shaun works as a diagnostic haematologist at the Alfred with a focus on flow cytometry where he has guided the development of a single-tube 10-colour ALL panel now utilised in routine testing at the Alfred.

Malgorzata (Gosia) Gorniak

Gosia Gorniak

Gosia Gorniak is currently employed as a Senior Scientist in the Clinical Flow Cytometry at Alfred Hospital in Melbourne. She is responsible for the daily supervision of the flow cytometry diagnostic services provided by Haematology Department including quality assurance activities. In addition to the routine clinical services she supports the unit and supervises the performance of the assays for Clinical Trials.

Clinical Flow at Alfred covers a wide range of test which include: lymphocytes subsets (T and B cells), CD34 counting and viability (fresh and frozen samples), FMH enumeration and the oncology immunophenotyping at diagnosis & disease monitoring that includes minimal residual disease.

Having worked in clinical flow cytometry for over 20 years Gosia has played a leading role in:

  • Development and application of 5, 8 and 10 colour flow cytometry diagnostic tests (including high sensitivity minimal residual disease monitoring).
  • Standardisation of protocols including an active involvement in Custom cocktails for 10c AML, NHL, B-ALL.
  • Supervision of data analysing, involved in creating the gating strategies and implementation of  Kaluza & Infinicyt software for MRD analysis.
  • Implementation of EuroFlow Next generation testing for MMMRD (Salamanca group).
  • Winner in individual category for  ‘Leading Innovation’ with recognition of our MRD work – Alfred Health in 2017.
  • Active in national assay guideline committees since 2016, involved in several of the taskforce committees currently updating the ACS Clinical Guidelines and international MM MRD proficiency analysis consortiums.

Dr George Grigoriadis

George Grigoriadis

George Grigoriadis is currently employed as a Clinical and Laboratory Haematologist at Monash Health and The Alfred.  He is also a Senior Lecturer at The School of Clinical Sciences at Monash Health, Monash University.

He is the Head of the Immunohaematology Research laboratory in the Centre for Cancer Research at Hudson Institute of Medical Research and a recipient of the Victorian Cancer Agency Clinical Research Fellowship undertaking research in understanding blood disorders in particular myeloma and myelodysplasia and translating these findings into improved patient outcomes.

Dr. Grigoriadis is the joint head of the myeloma service at Monash Health.

Dr Alvin Lo

Alvin Lo PhotoAlvin Lo is a WEHI Biologics fellow working in Wai-Hong Tham’s lab. He obtained his PhD in molecular microbiology from The University of Melbourne. He spent 5 years in Belgium at the Structural Biology Lab of the Free University of Brussels where he worked on small compound screening and the development of nanobodies against pathogenic bacteria. He then moved back to Australia and joined the School of Chemistry and Molecular Biosciences, University of Queensland and worked on the structural studies of virulence proteins involved in bacterial pathogenesis. Alvin is now at WEHI working on single B cell cloning for recombinant antibody production and the generation of alpaca nanobodies.

Dr Helen McGuire

Helen McGuire

Helen McGuire is a Senior Research Fellow at the Ramaciotti Facility for Human Systems Biology (RFHSB), an initiative established in 2013 to support the development of mass cytometry within NSW. Her research focus and interests lie in the clinical application of immunological studies to a range of human diseases, and she is particularly passionate about applying recent technological advances such as mass cytometry. Having extensively researched in this area, she is highly regarded for her expertise in utilising mass cytometry for clinical profiling. She coordinates collaborative projects within RFHSB across many diverse clinical applications. Collaborators span groups local to the University of Sydney campus and beyond.

Dr Fatima Valdes Mora

Fatima Valdes Mora

Fatima Valdes Mora is Group Leader of Histone Variants in the Genomics and Epigenetics Division at the Garvan Institute of Medical Research (Sydney, Australia). She obtained her PhD in Molecular Biology, Biochemistry and Biomedicine from CSIC (Autonoma University of Madrid, Spain) in 2008. She then moved to Sydney to spend 5 years at the Cancer Epigenetic lab headed by Professor Susan Clark lab at the Garvan Institute for Medical Research (Australia). She obtained her current Group Leader position at the Garvan Institute in 2014.

Fatima is a mid-career researcher arising as authority in Cancer epigenetics research; she has played an integral role in discovering novel genome-wide roles of the acetylation of the histone variant H2A.Z and enable of international significance. She has a passion for development and implementation of novel technology that has allow her to develop a strong multidisciplinary profile on cancer epigenetics, molecular and cellular biology, next-generation sequencing methodologies, single cell transcriptomics and epigenomics and bioinformatics interpretation of genome-wide data.

Associate Professor Paul Neeson

Paul Neeson

Paul Neeson completed a PhD at the University of Melbourne (Pathology), before doing a post-doc in the Paterson lab (University of Pennsylvania) where he worked on B-cell lymphoma vaccines. He returned to Melbourne and established the human immunology translational lab (HITRL) in Cancer Immunology Research at the Peter MacCallum Cancer Centre. The Lab’s focus is on chimeric antigen receptor (CAR) T cells for solid tumors and human immuno-oncology. His lab has adopted state-of-the-art technologies to explore the immune context of human cancer. This information is being used to better understand immune escape, to stratify patients for immunotherapy combination treatments (including CART cells) for better outcomes in patients with solid tumors.

Associate Professor Alex Swarbrick

Alex Swarbrick

Alex Swarbrick is an Associate Professor of Medicine at UNSW Sydney, Laboratory Head in the Garvan Institute of Medical Research, NHMRC Senior Research Fellow and co-head of the Breast Translational Oncology Program in the Kinghorn Cancer Center, Sydney. Alex completed his PhD at UNSW, followed by a postdoctoral fellowship with Nobel Laureate J. Michael Bishop at UCSF. Alex uses cell and molecular biology, animal models of disease and single cell genomics to find new treatment strategies for breast and prostate cancer.

Dr Charis Teh

Charis Teh

Charis Teh is a NHMRC Early Career Fellow at the Walter and Eliza Hall Institute of Medical Research. Charis received a BSc from ANU (2007), MPH from University of Sydney (2014) and PhD from the ANU (2012). She has developed technical expertise and knowledge in immunology, cancer, cell death, and mass cytometry technology at world-renowned laboratories – Prof Garry Nolan (Stanford University), Associate Prof Daniel Gray (WEHI) and Prof Christopher Goodnow (ANU). She is currently channelling her efforts to understand the survival and death signals that control immune cells and how this can be harnessed for treatment of autoimmunity and blood cancers.

Dr Elizabeth Todorova

Elizabeth Todorova

Elizabeth Todorova is a Laboratory Haematologist with more than 20 years of experience in clinical flow cytometry and morphology, as well as flow cytometry laboratory management.  Qualified as a medical doctor in 1985 in Bulgaria.  From 1997 to 2005 she has worked as a Head of Flow Cytometry Laboratory at Liverpool Hospital, Sydney, Australia. Since 2005 she is in charge of the Flow Cytometry Laboratory at Eastern Health Pathology, Teaching Hospital to the Monash Medical School, Melbourne, Australia.

Dr Todorova’s scientific interests lie in the field of Haematology and Neuroimmunohaematology. She is interested in studying the pathological changes of the lymphocyte subpopulations in CSF in inflammatory, demyelinating, autoimmune and oncological diseases of the nervous system.

Dr Mirjam van der Burg

Mirjam van der Burg

Mirjam van der Burg, PhD studied chemistry at the University of Leiden (1992-1997) and received her master in Biochemistry & Molecular biology ( cum laude ) in March 1997. In May 1997 she started her PhD training at the Dept. of Immunology of the Erasmus University on a project entitled Recombination processes during human B-cell differentiation. She defended her thesis in June 2002. Since January 2002 she is leader of the Workgroup Primary Immunodeficiencies, since 2018 at the Leiden University Medical Center. The PID laboratory of Mirjam van der Burg is an international reference center for diagnostics and research for SCID, DNA repair disorders and antibody deficiencies. The research lines are directly related to these entities and aim for identification of underlying genetic cause and studying the effect of the monogenetic defects on the immune system especially on B and T-cell differentiation and antigen receptor repertoire formation.

Her group is part of the Pediatric hematopoietic stem cell transplantation center of the Leiden University Medical Center, where she works on immune reconstitution post-HSCT in patients with PID. She is workgroup leader of the EuroFlow PID group, which aims for standardization of flow cytometric diagnosis for PID within Europe. Furthermore, she is project leader of the Dutch implementation pilot study for SCID in the neonatal screening program (SONNET, http://www.sonnetstudie.nl). Since 2014, she is board member of the European Society for Immunodeficiencies (ESID).

Associate Professor David Westerman

David Westerman

David Westerman is a University of Melbourne graduate with dual fellowships and has held his current position as Head of Haematopathology at Peter MacCallum Cancer Centre, since 2000. He is Deputy Director of the Dept of Pathology, Chair of the Transfusion Medicine Committee and holds honorary appointments with the University of Melbourne at St Vincent’s Hospital Clinical School, and the Sir Peter MacCallum Dept of Oncology. He is a member of the RCPA immunophenotyping committee. He has broad clinical and laboratory academic interests including teaching, flow cytometry, molecular haematology and biomarkers which are reflected by over 100 peer reviewed publications.

Associate Professor Menno van Zelm

Menno van Zelm

Menno van Zelm obtained his PhD from the Erasmus University in Rotterdam, the Netherlands (2007) and held postdoc positions at the University of California San Diego (USA) and the Erasmus MC (the Netherlands), prior to becoming Lab Head at the Erasmus MC (2010). In 2015, he was recruited to Monash University and the Alfred Hospital where he is currently Deputy Head (research) of Department.
Dr. van Zelm has received continuous fellowship support in the Netherlands and Australia (current NHMRC Senior Research Fellowship). In 2010, he received the Heineken Young Scientists Award from the Royal Netherlands Academy of Sciences (KNAW). Menno van Zelm is chair of the Nomenclature committee of the International Union of Immunological Societies (IUIS) and founding director of the JMF Centre for Immunodeficiencies in Melbourne. He runs a Translational Immunology programme with a focus on B-cell Biology, and is currently responsible for the careers of eleven people.